| 发明名称 |
ARGINNE DEIMINASE WITH REDUCED CROSS-REACTIVITY TOWARD ADI - PEG 20 ANTIBODIES FOR CANCER TREATMENT |
| 摘要 |
The present invention relates generally to isolated to arginine deiminase (ADI) proteins that have reduced cross-reactivity with anti-ADI-PEG 20 antibodies as compared to ADI-PEG 20, but which can have functional characteristics comparable to or better than ADI-PEG 20, compositions comprising the ADI proteins, and related methods of treating arginine-dependent diseases or related diseases such as cancer. |
| 申请公布号 |
US2014348814(A1) |
申请公布日期 |
2014.11.27 |
| 申请号 |
US201414214040 |
申请日期 |
2014.03.14 |
| 申请人 |
Polaris Group |
发明人 |
Almassy Robert;Showalter Richard E.;Thomson James A.;Sisson Wes;Shia Wei-Jong;Chen Li-Chang;Lee Yang |
| 分类号 |
A61K38/50;A61K45/06;C12N9/78 |
主分类号 |
A61K38/50 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A therapeutic composition comprising an isolated arginine deiminase, or a fragment thereof having ADI activity, and a pharmaceutically-acceptable carrier, wherein the isolated arginine deiminase has reduced cross-reactivity with patient anti-ADI-PEG 20 antibodies. |
| 地址 |
Grand Cayman KY |
